Lipocine
LPCN
50 hedge funds and large institutions have $28.9M invested in Lipocine in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 8 closing their positions.
37% more call options, than puts
Call options by funds: $430K | Put options by funds: $313K
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
0.31% less ownership
Funds ownership: 2.65% → 2.34% (-0.31%)
5% less capital invested
Capital invested by funds: $30.3M → $28.9M (-$1.4M)
14% less funds holding
Funds holding: 58 → 50 (-8)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.71M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$278K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$250K |
| 4 |
PP
PDT Partners
New York
|
+$182K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$337K |
| 2 |
Morgan Stanley
New York
|
-$125K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$96.4K |
| 4 |
SG Americas Securities
New York
|
-$71K |
| 5 |
Citigroup
New York
|
-$63.4K |
LPCN Hedge Fund Activity: Q1 2017 in Review
50 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2017, worth a combined $28.9M — down 4.6% from $30.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LPCN and 6 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 17 added.
The largest buyer was BlackRock, adding an estimated $3.71M. The largest seller was Millennium Management, cutting an estimated $337K.
- 50 institutional investors held Lipocine (LPCN) as of Q1 2017, down from 58 in Q4 2016.
- Funds reported $28.9M of Lipocine stock for Q1 2017, down 4.6% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q1 2017 and 8 closed out, a net change of -2 holders.
- The largest Lipocine buyer in Q1 2017 was BlackRock, an estimated $3.71M added.
- The largest Lipocine seller in Q1 2017 was Millennium Management, an estimated $337K sold.
Based on aggregated 13F filings for Q1 2017.